BG104880A - Medicamentous preparation for multiple sclerosis treatment - Google Patents

Medicamentous preparation for multiple sclerosis treatment

Info

Publication number
BG104880A
BG104880A BG104880A BG10488000A BG104880A BG 104880 A BG104880 A BG 104880A BG 104880 A BG104880 A BG 104880A BG 10488000 A BG10488000 A BG 10488000A BG 104880 A BG104880 A BG 104880A
Authority
BG
Bulgaria
Prior art keywords
medicamentous
multiple sclerosis
preparation
sclerosis treatment
treatment
Prior art date
Application number
BG104880A
Other languages
Bulgarian (bg)
Inventor
Иван ХРИСТОВ
Original Assignee
Иван ХРИСТОВ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иван ХРИСТОВ filed Critical Иван ХРИСТОВ
Priority to BG104880A priority Critical patent/BG104880A/en
Priority to PCT/BG2001/000016 priority patent/WO2002034199A2/en
Priority to AU2002210286A priority patent/AU2002210286A1/en
Publication of BG104880A publication Critical patent/BG104880A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The medicamentous form is administered for the treatment of multiple sclerosis. The form comprises the following components, in mg: zinc chlorate from 10.00 to 400.00, sodium salicylate from 1000.00 to 2000.00, nivalin from 5.00 to 20.00; vitamins: B12 from 1000.00 to 6000.00 g, B1 from 30.00 to 100.00, B2 from 5.00 to 20.00, B6 from 50.00 to 100.00, folic acid from 10.00 to 30.00, estriol (for women) from 0 to 1.00,or testosterone (for men), respectively, from 10.00 to 50.00, procaine (Novocain) from 20.00 to 80.00. The medicamentous form in injected intramuscularly in strictly specified places: in the occipital and the sacral regions, bilaterally. 4 claims
BG104880A 2000-10-24 2000-10-24 Medicamentous preparation for multiple sclerosis treatment BG104880A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BG104880A BG104880A (en) 2000-10-24 2000-10-24 Medicamentous preparation for multiple sclerosis treatment
PCT/BG2001/000016 WO2002034199A2 (en) 2000-10-24 2001-10-24 Medicine intended for treatment of multiple sclerosis
AU2002210286A AU2002210286A1 (en) 2000-10-24 2001-10-24 Medicine intended for treatment of multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG104880A BG104880A (en) 2000-10-24 2000-10-24 Medicamentous preparation for multiple sclerosis treatment

Publications (1)

Publication Number Publication Date
BG104880A true BG104880A (en) 2002-04-30

Family

ID=3928204

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104880A BG104880A (en) 2000-10-24 2000-10-24 Medicamentous preparation for multiple sclerosis treatment

Country Status (3)

Country Link
AU (1) AU2002210286A1 (en)
BG (1) BG104880A (en)
WO (1) WO2002034199A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009209B1 (en) * 2003-11-20 2007-12-28 Рихтер Гедеон Ведьесети Дьяр Рт. Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215224T2 (en) * 2002-02-21 2007-08-23 Schering Aktiengesellschaft PHARMACEUTICAL COMPOSITION, CONTAINING ONE OR MORE STEROIDS, ONE OR MORE TETRAHYDROFOLATE COMPOUNDS AND VITAMIN B12
PL1796692T3 (en) 2004-09-09 2012-08-31 Warburton Technology Ltd Trace elements
WO2009066138A2 (en) * 2007-11-22 2009-05-28 Promed Research Centre Stabilization of vitamin b complex and lidocaine hydrochloride injection
US20120058097A1 (en) * 2010-09-02 2012-03-08 Ms Therapeutics Limited Compositions including a sodium channel blocker and a b vitamin molecule and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009209B1 (en) * 2003-11-20 2007-12-28 Рихтер Гедеон Ведьесети Дьяр Рт. Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
WO2002034199A2 (en) 2002-05-02
AU2002210286A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
IL112518A0 (en) Thyroid hormone fast dispersing pharmaceutical composition
AU4451101A (en) Method and compositions for preventing hormone induced adverse effects
ATE238698T1 (en) NON-ALCOHOLIC BEVERAGE CONTAINING UBICHINONE
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
EP0783299A4 (en) Compounds and compositions for delivering active agents
AU3651895A (en) Use of aromatase inhibitors for the production of a pharmaceutical agent for treating a relative androgen deficiency in men
YU48559B (en) Pharmaceutical formulation for treating nicotine addiction
MXPA03010549A (en) Oxcarbazepine dosage forms.
EP0663835A1 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.
BG104880A (en) Medicamentous preparation for multiple sclerosis treatment
CA2133610A1 (en) Additive for Use in Feed for Sows and Feed for Sows
NZ326345A (en) Composition containing diosgenin
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
MY122477A (en) Sertraline oral concentrate
MD916G2 (en) Ungent for stomatologic deseases treatment
WO2001028570A3 (en) Zinc lactate lozenges and uses thereof
AU2002221567A1 (en) Use of an oestrogen in the manufacture of a composition containing oestrogen forthe treatment of atrophic vaginitis
DE69936773D1 (en) TREATMENT OF DEPRESSION AND COMPOSITIONS THEREOF
Korcok Canadian government study shows big rise in Canadian use of several narcotics.
MD1664F1 (en) Method of ulcer recidivation prophylaxis
UA29155A (en) METHOD OF TREATMENT OF THE THREAT OF PREMATURE BIRTH IN FEMALE DRUG ADDICTS
MD1715F1 (en) Method of prophylaxis and treatment of the precocious hypogalactia
CN1309967A (en) Acne treating skin care cream
UA36797A (en) method for intensive treatment of simple schizophrenia with suicide behaviour
UA36633A (en) method for treatment of paranoid schizophrenia with with suicide behaviour